File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/14728222.2017.1397134
- Scopus: eid_2-s2.0-85033218721
- PMID: 29065733
- WOS: WOS:000415630400007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Hepatitis B core protein as a therapeutic target
Title | Hepatitis B core protein as a therapeutic target |
---|---|
Authors | |
Keywords | cccDNA chronic hepatitis B core antigen core protein core protein allosteric modulator cure HBx protein immune response nucleocapsid surface antigen transcription translation virology |
Issue Date | 2017 |
Publisher | Taylor & Francis. The Journal's web site is located at http://www.tandfonline.com/iett |
Citation | Expert Opinion On Therapeutic Targets, 2017, v. 21 n. 12, p. 1153-1159 How to Cite? |
Abstract | Introduction: Chronic hepatitis B virus (HBV) infection is difficult to cure, due to the presence of covalently-closed-circular DNA and virus-mediated blunting of host immune response. Existing therapies with nucleos(t)ide analogue or pegylated-interferon are not sufficient to achieve a high rate of HBV surface antigen seroclearance, a more desirable treatment outcome. Novel therapeutic agents targeting alternative viral replication steps are being developed. In this review, we will discuss the hepatitis B core antigen (HBcAg) as a therapeutic target.
Areas covered: The basic structure and fundamental functions of HBcAg including nucleocapsid assembly, pre-genomic RNA encapsidation, reverse transcription, virion formation, cccDNA amplification, immune response regulation, and HBx protein interaction will be reviewed. Most of these are identified as therapeutic targets and tested in in vitro and in vivo studies, although clinical trials are scanty. Among the different components, the core protein allosteric modulators (CpAM) have been most widely investigated and appear promising in clinical trials.
Expert opinion: The multiple and essential functions of HBcAg for HBV life cycle are important and attractive targets for HBV therapeutic interventions. Controlled trials involving CpAM are awaited. Apart from CpAM, drugs directed against different functions of HBcAg may be further explored to maximize the chance of cure. |
Persistent Identifier | http://hdl.handle.net/10722/252169 |
ISSN | 2023 Impact Factor: 4.6 2023 SCImago Journal Rankings: 1.423 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2018-04-11T07:50:49Z | - |
dc.date.available | 2018-04-11T07:50:49Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Expert Opinion On Therapeutic Targets, 2017, v. 21 n. 12, p. 1153-1159 | - |
dc.identifier.issn | 1472-8222 | - |
dc.identifier.uri | http://hdl.handle.net/10722/252169 | - |
dc.description.abstract | Introduction: Chronic hepatitis B virus (HBV) infection is difficult to cure, due to the presence of covalently-closed-circular DNA and virus-mediated blunting of host immune response. Existing therapies with nucleos(t)ide analogue or pegylated-interferon are not sufficient to achieve a high rate of HBV surface antigen seroclearance, a more desirable treatment outcome. Novel therapeutic agents targeting alternative viral replication steps are being developed. In this review, we will discuss the hepatitis B core antigen (HBcAg) as a therapeutic target. Areas covered: The basic structure and fundamental functions of HBcAg including nucleocapsid assembly, pre-genomic RNA encapsidation, reverse transcription, virion formation, cccDNA amplification, immune response regulation, and HBx protein interaction will be reviewed. Most of these are identified as therapeutic targets and tested in in vitro and in vivo studies, although clinical trials are scanty. Among the different components, the core protein allosteric modulators (CpAM) have been most widely investigated and appear promising in clinical trials. Expert opinion: The multiple and essential functions of HBcAg for HBV life cycle are important and attractive targets for HBV therapeutic interventions. Controlled trials involving CpAM are awaited. Apart from CpAM, drugs directed against different functions of HBcAg may be further explored to maximize the chance of cure. | - |
dc.language | eng | - |
dc.publisher | Taylor & Francis. The Journal's web site is located at http://www.tandfonline.com/iett | - |
dc.relation.ispartof | Expert Opinion On Therapeutic Targets | - |
dc.rights | This is an electronic version of an article published inExpert Opinion On Therapeutic Targets, 2017, v. 21 n. 12, p. 1153-1159. Expert Opinion On Therapeutic Targets is available online at: https://doi.org/10.1080/14728222.2017.1397134 | - |
dc.subject | cccDNA | - |
dc.subject | chronic hepatitis B | - |
dc.subject | core antigen | - |
dc.subject | core protein | - |
dc.subject | core protein allosteric modulator | - |
dc.subject | cure | - |
dc.subject | HBx protein | - |
dc.subject | immune response | - |
dc.subject | nucleocapsid | - |
dc.subject | surface antigen | - |
dc.subject | transcription | - |
dc.subject | translation | - |
dc.subject | virology | - |
dc.title | Hepatitis B core protein as a therapeutic target | - |
dc.type | Article | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | postprint | - |
dc.identifier.doi | 10.1080/14728222.2017.1397134 | - |
dc.identifier.pmid | 29065733 | - |
dc.identifier.scopus | eid_2-s2.0-85033218721 | - |
dc.identifier.hkuros | 284785 | - |
dc.identifier.volume | 21 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 1153 | - |
dc.identifier.epage | 1159 | - |
dc.identifier.isi | WOS:000415630400007 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1472-8222 | - |